Pricing and reimbursement policies for digital therapeutics

ISPOR How Do the Pricing and Reimbursement Policies for Digital Therapeutics Compare and Contrast between the US, EU-5, China and JAPAN?


Digital therapeutics (DTx) are one of the categories of digital health, which is defined as products that deliver evidence-based therapeutic interventions to patients which are driven by high quality software programs to prevent, manage, or treat conditions. The Covid-19 pandemic accelerated the adoption of DTx globally. This study examines the pricing and reimbursement (P&R) policies for DTx in EU5, US, China and Japan.

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.